A randomized, placebo‐controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background and Aims: Fatigue is a common symptom of primary biliary cirrhosis (PBC), and is associated with an impaired quality of life. Study Question: No studies have assessed the use of modafinil in fatigue related to PBC in a controlled manner. Study Design, Measures, and Outcomes: A randomized, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of modafinil for the treatment of fatigue in PBC. Forty patients were randomized to modafinil (n = 20) or placebo (n = 20) for 12 weeks. A verbal report of fatigue for at least 6 months was required for enrollment. Modafinil was administered at 100 mg by mouth once daily; a change by 50 mg every 2 weeks (maximum: 200 mg once daily) was allowed, depending on the subject's response to treatment. The primary outcome was defined as a ≥50% improvement in fatigue severity [quantified by the Fisk Fatigue Impact Scale (FFIS)] after 12 weeks of treatment, compared with baseline values. Results: Thirty-three PBC patients completed the study. After 12 weeks of therapy, only 5 patients had a ≥50% reduction in FFIS scores: 3 patients (17.6%) in the modafinil arm and 2 (12.5%) in the placebo arm (P = 1.00). Change in median FFIS score was not statistically different between patients in the 2 treatment groups (P = 0.36). Modafinil was associated with minimal adverse events (headaches, diarrhea, and rash). Conclusions: In patients with PBC who have fatigue, treatment with modafinil for 12 weeks was safe and fairly well tolerated; however, it did not result in beneficial effects on fatigue compared with patients treated with placebo (CONSORT Table 1). ClinicalTrials.gov identifier NCT00943176.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Measuring the Functional Impact of Fatigue: Initial Validation of the Fatigue Impact Scale
Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.supplement_1.s79 · Cited by 1,541
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationPrince, M., Chetwynd, A., Newman, W., Metcalf, J. V., & James, O. F. W. (2002) · Gastroenterology · doi:10.1053/gast.2002.36027 · Cited by 348 · cited 1×
“4 mg/dL; (6) uncontrolled hypertension; (7) hypertension and left ventricular hypertrophy documented on electrocardiography in the last 2 years; (8) history of myocardial infarction or unstable angina within less than 6 months from study enrollment; (9) history of psychosis; (10) modification of treatment for underlyi…”
BackgroundTalwalkar, J. A., & Lindor, K. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13808-1 · Cited by 290
Self-citationCOMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Cited by
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“(186,187) However, a subsequent placebo-controlled trial failed to show benefit.(188) At this time, there is no recommended therapy for the fatigue resulting from PBC.”
BackgroundSelf-citationLleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
AASLD Practice Guidance: Palliative care and symptom‐based management in decompensated cirrhosis
Rogal, S. S., Hansen, L., Patel, A., Ufere, N. N., Verma, M., Woodrell, C. D., & Kanwal, F. (2022) · Hepatology · doi:10.1002/hep.32378 · Cited by 210
Current understanding of primary biliary cholangitis
Tanaka, A. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0028 · Cited by 158
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Metadata
- Authors
- Silveira, M. G., Gossard, A. A., Stahler, A. C., Jorgensen, R. A., Petz, J. L., Ali, A. H., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- American Journal of Therapeutics
- Published
- 2017-03
- Volume
- 24
- Issue
- 2
- Pages
- e167-e176
- ISSN
- 1075-2765 (ISSN-L)
- OpenAlex
- W2345548355
- Cited by
- 64
- References
- 44
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 6 · 2020: 7 · 2019: 5 · 2018: 8 · 2017: 3
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
- Keywords
- modafinil, primary biliary cirrhosis, fatigue, drug efficacy, drug safety, adverse events, quality of life
- MeSH terms
- Modafinil, Aged, Benzhydryl Compounds, Double-Blind Method, Fatigue, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Treatment Outcome, Wakefulness-Promoting Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, placebo‐controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. https://app.cochat.ai/papers/10.1097/mjt.0000000000000387
- The paper
- Silveira, M. G., Gossard, A. A., Stahler, A. C., Jorgensen, R. A., Petz, J. L., Ali, A. H., & Lindor, K. D. (2017). A randomized, placebo‐controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000000387
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.